Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: Involvement of the intrinsic pathway of apoptosis

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1160-1168

  Ismail, Bassel ^a   Ghezali, Lamia ^a   Gueye, Rokhaya ^b   Limami, Youness ^a   Pouget, Christelle ^b   Leger, David Y ^a   Martin, Frederique ^a   Beneytout, Jean Louis ^a   Duroux, Jean Luc ^a   Diab Assaf, Mona ^c   Fagnere, Catherine ^b   Liagre, Bertrand ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b Organic Chemistry and Therapeutic Laboratory   (United States)

^c LEBANESE UNIVERSITY   (Lebanon)

Author keywords

Apoptosis; Chalcones; Cyclooxygenase 2; NF B; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CHALCONE DERIVATIVE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RG 003; RG 005; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; CYCLOOXYGENASE 2; DNA FRAGMENTATION; HUMANS; MALE; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84882363844     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2024     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Dreicer R: Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. Urol Oncol 26: 426-429, 2008.
3. Alcaraz MJ, Vicente AM, Araico A, Dominguez JN, Terencio MC and Ferrándiz ML: Role of nuclear factor-kappaB and heme oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. Br J Pharmacol 142: 1191-1199, 2004.
4. Domínguez JN, León C, Rodrigues J, Gamboa de Domínguez N, Gut J and Rosenthal PJ: Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J Med Chem 48: 3654-3658, 2005.
5. Liu X and Go ML: Antiproliferative activity of chalcones with basic functionalities. Bioorg Med Chem 15: 7021-7034, 2007.
6. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
7. Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4: 721-729, 2003.
8. Shen KH, Chang JK, Hsu YL and Kuo PL: Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin Pharmacol Toxicol 101: 254-261, 2007.
9. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
10. Xie WL, Chipman JG, Robertson DL, Erikson RL and Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692-2696, 1991.
11. Gupta S, Srivastava M, Ahmad N, Bostwick DG and Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78, 2000.
12. Wenzel U, Kuntz S, Brendel MD and Daniel H: Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 60: 3823-3831, 2000.
13. Corbiere C, Liagre B, Terro F and Beneytout JL: Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell Res 14: 188-196, 2004.
14. Smiley ST, Reers M, Mottola-Hartshorn C, et al: Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88: 3671-3675, 1991.
15. Lepage C, Liagre B, Cook-Moreau J, Pinon A and Beneytout JL: Cyclooxygenase-2 and 5-lipoxygenase pathways in diosgenin induced apoptosis in HT-29 and HCT-116 colon cancer cells. Int J Oncol 36: 1183-1191, 2010.
16. Leger DY, Liagre B and Beneytout JL: Role of MAPKs and NF-B in diosgenin-induced megakaryocytic differentiation and subsequent apoptosis in HEL cells. Int J Oncol 28: 201-207, 2006.
17. Bertrand J, Liagre B, Ghezali L, Beneytout JL and Leger DY: Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents. Apoptosis 18: 836-850, 2013.
18. Ghezali L, Leger DY, Limami Y, Cook-Moreau J, Beneytout JL and Liagre B: Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptotic effect. Exp Cell Res 319: 1043-1053, 2013.
19. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
20. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
21. MacKenzie SH, Schipper JL and Clark AC: The potential for caspases in drug discovery. Curr Opin Drug Discov Dev 13: 568-576, 2010.
22. Liu YQ, Hu XY, Lu T, Cheng YN, Young CY, Yuan HQ and Lou HX: Retigeric acid B exhibits antitumor activity through suppression of nuclear factor-B signalling in prostate cancer cells in vitro and in vivo. PLoS One 7: e38000, 2012.
23. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
24. Giri K and Aggarwal BB: Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273: 14008-14014, 1998.
25. Wang D and Dubois RN: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788, 2010.
26. Kirschenbaum A, Liu X, Yao S and Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urology 58: 127-131, 2001.
27. Lee KS, Lee HJ, Ahn KS, et al: Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 280: 93-100, 2009.
28. Hankey BF, Feuer EJ, Clegg LX, et al: Cancer surveillance series: Interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017-1024, 1999.
29. Ganesh B, Saoba SL, Sarade MN and Pinjari SV: Risk factors for prostate cancer: an hospital-based case-control study from Mumbai, India. Indian J Urol 27: 345-350, 2011.
30. American Dietetic Association; Dietitians of Canada: Position of the American Dietetic Association and Dietitians of Canada: Vegetarian diets. J Am Diet Assoc 103: 748-765, 2003.
31. Hsing AW and Chokkalingam AP: Prostate cancer epidemiology. Front Biosci 11: 1388-1413, 2006.
32. Rodrigues J, Abramjuk C, Vásquez L, et al: New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer. Pharm Res 28: 907-919, 2011.
33. Deb Majumdar I, Devanabanda A, Fox B, Schwartzman J, Cong H, Porco JA Jr, and Weber HC: Synthetic cyclohexenyl chalcone natural products possess cytotoxic activities against prostate cancer cells and inhibit cysteine cathepsins in vitro. Biochem Biophys Res Commun 416: 397-402, 2011.
34. Nagaraju M, Gnana Deepthi E, Ashwini C, et al: Synthesis and selective cytotoxic activity of novel hybrid chalcones against prostate cancer cells. Bioorg Med Chem Lett 22: 4314-4317, 2012.
35. Jung JI, Lim SS, Choi HJ, et al: Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J Nutr Biochem 17: 689-696, 2006.
36. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
37. Zamzami N, Susin SA, Marchetti P, et al: Mitochondrial control of nuclear apoptosis. J Exp Med 183: 1533-1544, 1996.
38. Green D and Kroemer G: The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 8: 267-271, 1998.
39. Liu X, Kim CN, Yang J, Jemmerson R and Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-157, 1996.
40. Lebedeva IV, Sarkar D, Su ZZ, et al: Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758-8773, 2003.
41. Salvesen GS and Dixit VM: Caspases: intracellular signalling by proteolysis. Cell 91: 443-446, 1997.
42. D'Amours D, Desnoyers S, D'Silva I and Poirier GG: Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342: 249-268, 1999.
43. Nicholson DW: Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6: 1028-1042, 1999.
44. Chen X, Thakkar H, Tyan F, et al: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083, 2001.
45. Murillo H, Huang H, Schmidt LJ, Smith DI and Tindall DJ: Role of PI3K signalling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805, 2001.
46. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
47. Madrid LV, Mayo MW, Reuther JY and Baldwin AS Jr: Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276: 18934-18940, 2001.
48. Ahn KS, Sethi G and Aggarwal BB: Nuclear factor-kappa B: from clone to clinic. Curr Mol Med 7: 619-637, 2007.
49. Yang P, Cartwright CA, Li J, et al: Arachidonic acid metabolism in human prostate cancer. Int J Oncol 41: 1495-1503, 2012.
50. Narayanan NK, Narayanan BA and Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-B, and steroid hormone receptors. Int J Oncol 26: 785-792, 2005.
51. Sarveswaran S, Gautam SC and Ghosh J: Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKC without inhibiting Akt. Int J Oncol 41: 2191-2199, 2012.
52. Patsos HA, Greenhough A, Hicks DJ, et al: The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int J Oncol 37: 187-193, 2010.
53. Limami Y, Pinon A, Leger DY, et al: HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death. Biochimie 93: 749-757, 2011.
54. Limami Y, Pinon A, Leger DY, et al: The P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells. Biochimie 94: 1754-1763, 2012.
55. Mencher SK and Wang LG: Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5: 3, 2005.
56. Trouillas P, Corbière C, Liagre B, Duroux JL and Beneytout JL: Structure-function relationship for saponin effects on cell cycle arrest and apoptosis in the human 1547 osteosarcoma cells: a molecular modelling approach of natural molecules structurally close to diosgenin. Bioorg Med Chem 13: 1141-1149, 2005.